FOSUN HEALTH Logo

Bone & Soft Tissue Tumors Overview

catalogue

Bone & Soft Tissue Tumors Overview

Bone & Soft Tissue Tumors Overview

A lump in a limb and a pain in a bone are two of the most common reasons to see a doctor, and most of the time neither is a tumor. When one of them is a sarcoma, what decides the outcome is not how dramatic the presentation was but the order in which the problem is handled: the right images read early, the tissue sampled by a biopsy that is planned together with the operation, and a first operation that removes the tumor with a margin of normal tissue around it. Everything else — chemotherapy, radiotherapy, targeted drugs, reconstruction — is arranged around that sequence.

Bone & Soft Tissue Tumors Overview
  • Written opinion from a sarcoma team once complete records arrive

  • The biopsy and the operation are planned together, never in sequence

  • The one that decides whether the tumor is removed completely

  • The original site, and the lungs

What bone and soft tissue tumors are — one family, not one disease

Bone and soft tissue tumors are named after the tissue they come from rather than after the place they sit. Bone, cartilage, fat, muscle, blood vessels, nerves and the fibrous tissue that holds a limb together all have cells that can multiply abnormally, and each gives rise to its own group of tumors. That is why the term covers so much ground: a tumor of cartilage cells and a tumor of fat cells can sit in the same thigh, look similar on a scan and behave in completely different ways.

The word tumor does not mean cancer. A tumor is a lump of cells that has grown where it should not, and the great majority of lumps in limbs are benign: a lipoma of fat, a haemangioma of vessels, a cartilaginous growth on the surface of a bone, a nerve sheath tumor, a fluid-filled ganglion. These can be uncomfortable, can be removed for that reason, and do not spread. The malignant members of the family — the sarcomas — are the ones that can grow into the tissue around them and travel to distant organs, and they are the reason this page exists.

There is a second distinction worth making at the start, because it changes everything downstream. A cancer that began somewhere else and has spread to the skeleton is not a bone tumor; it is that cancer, in bone, and it is treated by the team looking after the original cancer. That situation is covered separately in our bone metastasis guide. Here we deal with tumors that begin in the skeleton or in the soft tissues around it — the primary tumors.

What holds the family together is not a shared appearance but a shared way of working, and it comes from one fact: the first operation is decisive. A sarcoma removed whole, with a margin of normal tissue around it, gives the patient the best chance there is; a sarcoma removed piecemeal, or entered without a plan, is a much harder problem even if it is then treated perfectly. So the sequence is fixed. Image the whole region before touching anything. Sample the tissue in a way that can be removed later with the tumor. Name the tumor and grade it. Stage it. Then operate.

The main types, and why the type decides the treatment

Tumors of bone are given names that describe what the cells are trying to make. Osteosarcoma forms bone and is the type seen most often in adolescents and young adults, typically around the knee or the shoulder. Chondrosarcoma forms cartilage and appears more often in mid and later adult life, in the pelvis, the shoulder girdle or a long bone. Ewing sarcoma is a small round cell tumor of bone and of the soft tissue around it, and it behaves as a whole-region problem rather than a lump. Giant cell tumor of bone sits at the end of a long bone, usually after the growth plates have closed; it is locally aggressive rather than a typical spreading cancer, and it has its own treatments.

Tumors of soft tissue are named after the tissue they resemble. Liposarcoma comes from fat. Undifferentiated pleomorphic sarcoma is a tumor that has lost its resemblance to any one tissue and is common in the thigh. Synovial sarcoma arises near joints and tendons, often in a limb of a young adult, and can be small and slow for a long time. Leiomyosarcoma comes from smooth muscle, malignant peripheral nerve sheath tumor from the sheath of a nerve, myxofibrosarcoma from the connective tissue of the limbs, and dermatofibrosarcoma protuberans from the skin's deep layer, where it grows slowly and rarely spreads. Gastrointestinal stromal tumor arises in the wall of the gut and belongs to the same family of connective tissue tumors, though it is treated by a different route.

TypeTissue it comes fromWhere it usually appearsWhat the name decides
OsteosarcomaBone-forming cellsAround the knee or the shoulder, in adolescents and young adultsSystemic chemotherapy is part of the plan, given before the operation as well as after
ChondrosarcomaCartilage-forming cellsPelvis, shoulder girdle or a long bone, more often in later adult lifeUsually treated by surgery alone; it does not respond to the drugs used for other sarcomas
Ewing sarcomaSmall round cells of bone and of the soft tissue around itLong bones, the pelvis and the chest wall, most often in children and young adultsChemotherapy and radiotherapy are both active, so treatment is whole-region rather than local
Giant cell tumor of boneCells that break bone downThe end of a long bone, usually after the growth plates have closedLocally aggressive rather than typically spreading; has drug treatment of its own
ChordomaRemnants of the tissue that formed the spineThe base of the skull and the lower spineRelies on complete removal and on radiotherapy given with precision
LiposarcomaFat cellsThigh and the space behind the abdominal cavityThe subtype decides whether radiotherapy is used around the operation
Undifferentiated pleomorphic sarcomaNo resemblance to one tissueThigh and other large muscle groups of adultsTreated mainly by surgery with radiotherapy where the margin is close
Synovial sarcomaThe tissue around joints and tendonsLimbs of young adults; can be small and slowDefined by a molecular change, and chemotherapy has a role in the types that respond
LeiomyosarcomaSmooth muscleLimbs, the uterus and the vesselsSurgery first; the site and grade decide what is added
Malignant peripheral nerve sheath tumorThe sheath around a nerveWhere a large nerve runs, sometimes in people with neurofibromatosis type 1Removal with a margin; radiotherapy where the margin is close
MyxofibrosarcomaConnective tissue of the limbsArms and legs of older adultsProne to returning locally, so the field treated around the operation matters
Dermatofibrosarcoma protuberansThe deep layer of the skinTrunk and limbs, growing slowlyRemoved with a wide margin; rarely spreads
Gastrointestinal stromal tumorThe wall of the gutStomach and small bowelDriven by a change that a targeted drug acts on, which is the treatment backbone

The list matters because the name is not a label for the patient to carry; it is a treatment decision in advance. A tumor that responds to systemic treatment is treated with it — osteosarcoma and Ewing sarcoma are, which is why chemotherapy is given before the operation rather than only after it. A tumor that responds to radiotherapy is treated with it, which is why most soft tissue sarcomas are given radiotherapy around the operation while most bone sarcomas are not. A tumor defined by a specific molecular change can be treated by a drug aimed at that change, which is the case for gastrointestinal stromal tumor. And a tumor that neither responds to nor needs the systemic treatments is treated by surgery alone, done well, with nothing added for its own sake.

The benign lookalikes are part of this section for a practical reason: they are the reason most lumps do not need an operation, and telling them apart is an imaging decision before it is a surgical one. A well-defined lipoma of fat, a harmless cartilage cap on the surface of a bone, a small cartilaginous island inside one, a nerve sheath tumor that lights up in a characteristic way — each has an appearance that imaging can recognise with reasonable confidence, and each is usually left alone or watched.

Staging: size, depth and grade — and why the margin is the real measure

Staging answers two questions at once: how far the tumor has already reached, and how likely it is to come back if it is simply removed. Four dimensions are combined to answer them. The size of the tumor, measured on the scan rather than by hand. Its depth — whether it sits above or below the layer of fibrous tissue that wraps the muscles of a limb, because a tumour below that layer behaves differently from one above it. Its grade, read by the pathologist from the tissue and reflecting how much the cells resemble normal tissue and how fast they are dividing. And whether it has already spread, which for most sarcomas means looking at the lungs first.

Bone tumors and soft tissue tumors are staged with different systems and this is worth knowing, because patients see the words. Tumors of bone are usually described using the surgical staging used by musculoskeletal tumour surgeons, which combines the grade with whether the tumor is confined to the bone or has broken into the surrounding soft tissue, and whether it has spread. Soft tissue sarcomas are described using the tumour, node and metastasis system, with the grade and the depth added. The systems are different because the diseases are different: a sarcoma of soft tissue spreads through the blood, and lymph nodes are involved in a minority of types, so the node category means less than it does in, for example, breast or bowel cancer.

What staging does not do is decide the operation on its own, and this is the point most often missed. A small, low-grade tumor in the fat of a forearm and a large, high-grade tumor deep in the thigh may be given different stage descriptions and still be treated with the same principle: remove it with a margin of normal tissue. What changes is everything around the operation — whether systemic treatment is given first, whether radiotherapy is added, how wide the removal has to be, and how the limb is rebuilt afterwards.

Which brings the page to the measurement that carries the most weight, and it is not part of the stage at all: the margin. Whether the tissue around the removed tumor is free of tumor cells is the single strongest determinant of whether the tumor returns where it was. A positive margin usually means either further surgery or radiotherapy to the area, and both are easier to plan for than to add later. This is why the biopsy is not a separate event from the operation, why the surgeon who will remove the tumor should be involved before the tissue is sampled, and why a first operation done in the wrong order is the most expensive mistake in this family of diseases — expensive in limb, in function and in time.

What the tissue test adds — the changes that name a sarcoma

Many sarcomas are defined by a specific change in the genetic material of the tumor cells, and for those tumors the change is the diagnosis. A translocation joins two genes that should be apart, and the resulting fusion is characteristic of the type. Ewing sarcoma is defined by a fusion involving the EWSR1 gene. Synovial sarcoma by one involving SS18. Myxoid liposarcoma by one involving DDIT3. When the tissue under the microscope is ambiguous — a small round cell tumor, a spindle cell tumor without an obvious tissue of origin — testing for these fusions turns a description into a name, and the name is what selects the treatment.

Other types are defined by a different kind of change. Well-differentiated and dedifferentiated liposarcoma show extra copies of the MDM2 and CDK4 genes, which separates them from benign fatty tumors that look similar. Gastrointestinal stromal tumor is driven by changes in KIT or PDGFRA, and this is not an academic point: it is the reason a drug aimed at that pathway works in this tumor when it would not in most others. Loss of a protein called INI1 points to epithelioid sarcoma and a small group of related tumors. And a small number of sarcomas carry a fusion involving NTRK, which matters because drugs aimed at that fusion are available for tumors that carry it wherever they started.

Two practical consequences follow. The first is that the test has to be ordered on tissue that is adequate for it, and this is a reason for the biopsy to be done at a centre where the pathologist expects to do molecular work rather than at the nearest available place. The second is that the test has to be done before treatment starts where possible: chemotherapy and radiotherapy change the tissue, and a diagnosis that rests on a molecular change is easier to make on the untreated sample.

What molecular testing does not do is replace the microscope or the scan. It answers a narrow question — is this the tumor we think it is — with more certainty than appearance alone can, and it occasionally redirects a plan entirely when it identifies a tumor that has a drug of its own. That is the whole of its value, and it is a substantial one.

Why patients come to China for bone and soft tissue tumor care

Tumors of bone and soft tissue are decided by a combination of capabilities rather than by any single one, and it is the combination that patients travel for. The first is a plan made by the people who will carry it out: the surgeon who will remove the tumor, the radiologist reading the extent of it, the pathologist who will name it, and the oncologist who will decide whether systemic treatment comes before or after the operation, working from one plan rather than from a referral chain.

The second is the order of events. The biopsy is planned with the operation that will follow it, so that the track the needle takes can be removed together with the tumor, and so that the biopsy does not cross a compartment that must stay clean. This is a decision made before the first needle, and it is the single most consequential thing that can be got right or wrong early in the illness.

The third is the surgical range, and it is here that the honest sentence belongs: limb-sparing surgery is possible for most tumors of the arms and legs, and it depends on removing the tumor with a margin, which sometimes means removing a segment of bone or a muscle group and rebuilding what is left. Where the tumor cannot be removed with a safe margin in any other way, amputation remains the correct operation, and a service that offers it is not a service that has failed. Reconstruction uses the tools the case calls for — a tumor prosthesis, a bone graft, a transfer of the patient's own bone with its blood supply kept intact — chosen around the patient's age, the segment involved and what they want to return to.

Around these three, the practical arrangements are the ones that matter to a family arranging travel. Records reviewed by the sarcoma team receive a written opinion within about 48 hours of complete records arriving, and that opinion states what the imaging shows, what the biopsy found if it has been done, and what the next step should be. Imaging, histology and molecular results are reviewed together rather than in sequence. Our network treats patients from more than 124 countries and territories, 19 institutions work from shared protocols, and more than 55 insurers bill directly — with costs that are a fraction of those for equivalent treatment in Europe or the United States.

Frequently Asked Questions

Is a lump in my arm or leg usually a tumor?

No. The great majority of lumps in limbs are benign — fat, vessels, fibrous tissue, nerve sheath or a fluid-filled sac — and are diagnosed by their appearance on imaging. What changes the assessment is not the presence of a lump but its behaviour: whether it is enlarging over weeks and months, whether it sits deep to the muscle layer rather than in the fat, whether it is firm and fixed to what lies beneath it, and whether it is larger than a golf ball. Those features decide who needs imaging, and imaging decides who needs a biopsy.

Is this the same as cancer that has spread to the bone?

No, and the two are treated in opposite directions. A cancer that began in the breast, lung, prostate or elsewhere and has spread to the skeleton is that cancer, in a new place, and it is managed by the team treating the original disease — that is covered in our bone metastasis guide. A primary bone or soft tissue tumor began in the skeleton or in the tissue around it, and it is staged and treated as a disease of its own. The distinction is not academic: the two have different treatments, and the primary tumors are the ones where a first operation with a margin can be curative.

Did an injury cause this?

No. There is a consistent pattern where a sarcoma is noticed after a knock, a fall or a sports injury, and the sequence is the opposite of what it looks like: the tumor was already there, and the injury drew attention to it. This matters because it delays the diagnosis when the pain is attributed to the injury and watched for weeks. Pain or a lump that persists after a minor injury — particularly pain present at rest or at night — deserves imaging rather than a longer period of observation.

Can the limb always be saved?

It can be saved in most tumors of the arms and legs, but not in all, and it depends on the margin rather than on the surgeon's preference. The question that comes first is whether the tumor can be removed completely while leaving a limb that works; when it cannot, amputation is the operation that removes the disease, and it is a treatment rather than a failure. The decision belongs to a conversation about what the patient wants to be able to do afterwards, held before the operation rather than after it.

Send the MRI, not only the report

Send the MRI images themselves along with the radiograph, the biopsy and pathology report, any molecular testing already done, the operative notes if an operation has taken place, and the imaging of the chest. A sarcoma team reads the images rather than the summary, and it can say whether the biopsy was taken in a way that keeps every treatment option open — which is often the question that decides everything that follows.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

WhatsApp +86 172-7459-8280 · EN / 中文 · 24h within business hours

Follow Fosun Health

Apply for an Appointment

Do you have test results*